Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
351 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (1)
  • Closed (27)

Medical Condition

  • Show all (1900)
  • Addiction (16)
  • Allergy, Asthma, & Immunology (12)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (38)
    • (-) Amyloidosis (13)
    • Anemia (1)
    • Sickle Cell Disease (5)
  • Bone & Muscle (10)
  • Cancer (726)
  • Child Development (4)
  • COVID-19 (Coronavirus) (37)
  • Critical Illness (1)
  • Dental (2)
  • Developmental Disorders (2)
  • Diabetes (22)
  • Ear, Nose and Throat (11)
  • Endocrine & Metabolic Disease (13)
  • Eye (8)
  • Gastrointestinal and Digestive Diseases (22)
  • Hair and Skin Disorders (2)
  • Headaches (5)
  • Healthy Volunteers (175)
  • Heart Disease (128)
  • Infectious Disease (48)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (48)
  • Lung Disease (32)
  • Meniere's Disease (1)
  • Neurological Disorders (174)
  • Nutrition (4)
  • Obesity (9)
  • Obstetrics & Gynecology (51)
    • Abdominal Cramping (1)
    • (-) Contraception (15)
    • Fertility (2)
    • Preeclampsia (1)
    • Pregnancy (16)
    • Prenatal Abnormalities (1)
    • Reproductive & Hormonal Disorders (2)
  • Pain Management (1)
  • Pediatrics (104)
  • Psychiatric Disorders (65)
  • Rehabilitation (8)
  • Stroke (7)
  • Surgery (7)
  • Transplant (51)
  • Urology (4)
  • Vascular Conditions (9)
Displaying 1 - 28 of 28

Study of ABBV-383 in Patients with Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the…
Read More

Study of Birtamimab in Patients with Mayo Stage IV (AL) Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Rajshekhar Chakraborty, MD
Status: Closed
The purpose of this study is to evaluate whether birtamimab plus standard of care will improve survival in subjects with Mayo Stage IV AL amyloidosis. Birtamimab has not yet been approved by the Food and Drug Administration (FDA). During the first phase of the study, the purpose of this study is to evaluate whether birtamimab plus standard of care will…
Read More

Ovaprene Non-Hormonal Contraceptive Ring Study

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
Ovaprene, is an experimental monthly non-hormonal intravaginal contraceptive being developed as a possible new method of birth control. It consists of a round piece of woven material surrounded by a soft, flexible rubber ring. The ring itself is made of a silicone rubber combined with the following ingredients: ferrous gluconate (a type of iron), Vitamin C…
Read More

Study Seeking to Evaluate the Effectiveness of LB as a Possible Injection Contraception Method (Females Age 18-40)

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
The study is looking to evaluate levonogestrel butanoate as a possible new long-acting injectable for birth control. Levonogestrel butanoate is a type of hormone called progestin that has a long history of clinical use in a variety of birth control methods (e.g. pills, intrauterine devices, implants) and its efficacy and safety are well recognized. This…
Read More

A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects.
Read More

A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3a of amyloid light chain (AL) amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to…
Read More

New Birth Control Pill Study

Condition: Obstetrics & Gynecology / Contraception
Investigator: Carolyn Westhoff, MD
Status: Closed
If you are a woman between the ages of 18 and 35, are pre-menopausal, sexually active and do NOT wish to become pregnant, you are invited to see if you may qualify for a research study. The purpose of this research study is to test the effectiveness of an investigational oral birth control pill. If you qualify, you will receive investigational study…
Read More

Study of STI-6129 in Patients with Relapsed or Refractory Systemic AL Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an antibody drug (STI-6129) in patients with AL amyloidosis that has returned or has not responded to treatment (relapsed/refractory). The study drug (STI-6129) will be given in 3 injections through a needle, into a vein as an intravenous (IV), with 21 days between each injection.
Read More

VeraCept Phase III

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
We are asking you to participate in this research study because you are a woman of child-bearing age or potential and interested in using an intrauterine device (IUD) for birth control for up to 5 years.
Read More

Birth control research study of an investigational intrauterine copper contraceptive

Condition: Obstetrics & Gynecology / Contraception
Investigator: Carolyn Westhoff, MD
Status: Closed
There are over 62 million US women in their child-bearing years, ages 15-44. Thirty-eight million use some form of contraception which included permanent sterilization (tubal ligation or vasectomyin male partner), contraceptive implants, intrauterine devices, injections, pills, patches, vaginal spermicides, and behavioral methods such as coitus interrupts…
Read More

Study For Previously Treated Patients Of Amyloidosis Using Bendamustine and Dexamethasone

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment. Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the…
Read More

Study of Extended Use of Mirena Beyond 5 Years in Women

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
Do You Have a Mirena IUD? You may qualify for a study on the extended use of the Mirena IUD! You may qualify if you are 18 to 33 years old and had your Mirena placed in 2013. Compensation available for time and effort. Find out if you qualify!
Read More

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…
Read More

A study for women using contraceptive study drug LF111

Condition: Obstetrics & Gynecology / Contraception
Investigator: Anne Davis, MD
Status: Closed
The purpose of this study is to find out how safe and effective investigational birth control pill, LF111 may be as a contraceptive, how it affects women's menstrual bleeding patterns, and how long LF111 stays in women's bodies. Participants will take the new experimental birth control pill for one year, and will come to the medical center for 8…
Read More

A study for healthy, sexually active women using a hormone-releasing intrauterine contraceptive called LevoCept

Condition: Obstetrics & Gynecology / Contraception
Investigator: Carolyn Westhoff, MD
Status: Closed
This is a study looking to evaluate how well a new hormone-releasing Intrauterine Contraceptive called LevoCept works in healthy, sexually active women. The study will consist of 6 study visits including a screening visit prior to enrollment and monthly telephone calls over the course of a year. The study visits will vary but mostly consist of physical and…
Read More

Study Comparing Two Copper IUDs

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
Columbia University is conducting a contraceptive clinical trial looking at two intrauterine devices, one of which is investigational. Pre-menopausal women ages 16-40 who are generally healthy, sexually active, at risk for pregnancy, and are not at risk for sexually transmitted infections may qualify.
Read More

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Read More

A study for healthy women seeking birth control using Agile contraceptive patch, AG200-15

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
The purpose of this study is to assess the effectiveness of AG200-15 which is an investigational birth control patch. AG200-15 is an investigational birth control patch being developed for use by women who wish to use a skin patch to prevent pregnancy. It contains LNG (levonorgestral) and EE (ethinyl estradiol), which are female sex hormones and are active…
Read More

A study looking at the effectiveness and safety of a new hormonal IUD (Intrauterine Device)

Condition: Obstetrics & Gynecology / Contraception
Investigator: Carolyn Westhoff, MD
Status: Closed
This study will look at the safety and effectiveness of a new hormonal IUD. This IUD is a small device that a clinician will place in your uterus. It contains a progestin (a hormone) that releases a small amount of hormone to prevent pregnancy. Once the device is in, you will come in for periodic study visits over the course of a year.
Read More

A study for women who want permanent birth control without surgery

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
The purpose of this study is to test the safety of the FemBloc Permanent Contraceptive System as a method to prevent pregnancy.
Read More

Phase 3 study of safety and efficacy of Daratumumab in combination with other drugs in treating AL Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to see if daratumumab when given with three other drugs cyclophosphamide, bortezomib (VELCADE) and dexamethasone is useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis). The study will look at what happens (both good and bad) when daratumumab is given with these three drugs compared to…
Read More

E4 Birth Control Pill Study

Condition: Obstetrics & Gynecology / Contraception
Investigator: Carolyn Westhoff, MD
Status: Closed
This study is studying the effectiveness and safety of a new birth control pill. The pill contains two hormones, drospirenone (a progestin) and estetrol (an estrogen), which combine to prevent pregnancy. Scientists think that estetrol may be safer and have more benefits than other estrogen hormones. The study lasts about one year, and you will come in for 7…
Read More

A study for patients with AL amyloidosis using study drug NEOD001

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected…
Read More

Contraceptive Vaginal Ring

Condition: Obstetrics & Gynecology / Contraception
Investigator: Paula Castano, MD, MPH
Status: Closed
Hormonal Vaginal Ring for Contraception
Read More

Study For Previously Treated Patients Of Light-Chain Amyloidosis Using study drugs Dexamethasone and MLN9708

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to find out if MLN9708 plus dexamethasone improves against systemic light chain amyloidosis better than the physicians choice chemotherapy treatment. Physicians choice chemotherapy treatment is a treatment regimen that is commonly used to treat amyloidosis patients. The study will also determine if MLN9708 plus dexamethasone can…
Read More

Study of ION-682884 (SC) in patients with TTR Amyloidosis Polyneuropathy

Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
Read More

Help us learn how Emergency Contraception (EC) is absorbed

Condition: Obstetrics & Gynecology / Contraception
Investigator: Carolyn Westhoff, MD
Status: Closed
The unintended pregnancy rate is rising despite increased availability and use of different types of emergency contraception (EC) pills. Few studies have addressed reasons for EC failure, yet such an investigation may allow researchers to better understand if EC can be used more successfully.Recently studies have shown that EC failure rates are higher in…
Read More

Study For Previously Treated Patients Of Light-Chain Amyloidosis Using Study Drug Carfilzomib

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science